UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 37,468 Shares of Sotera Health (NASDAQ:SHC)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Sotera Health (NASDAQ:SHC - Free Report) by 14.3% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 299,463 shares of the company's stock after purchasing an additional 37,468 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.11% of Sotera Health worth $4,097,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in SHC. Barclays PLC grew its position in Sotera Health by 169.8% in the 3rd quarter. Barclays PLC now owns 473,597 shares of the company's stock worth $7,909,000 after purchasing an additional 298,085 shares during the period. Blue Trust Inc. grew its position in Sotera Health by 164.3% in the 4th quarter. Blue Trust Inc. now owns 1,834 shares of the company's stock worth $25,000 after purchasing an additional 1,140 shares during the period. Pacer Advisors Inc. grew its position in Sotera Health by 9.0% in the 4th quarter. Pacer Advisors Inc. now owns 34,773 shares of the company's stock worth $476,000 after purchasing an additional 2,866 shares during the period. Empowered Funds LLC bought a new stake in Sotera Health in the 4th quarter worth approximately $351,000. Finally, Entropy Technologies LP bought a new stake in Sotera Health in the 4th quarter worth approximately $229,000. 91.03% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on SHC. The Goldman Sachs Group raised shares of Sotera Health from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $14.00 to $17.00 in a research report on Monday, May 5th. Piper Sandler cut their price objective on shares of Sotera Health from $15.00 to $13.00 and set a "neutral" rating for the company in a research report on Wednesday, April 23rd. Finally, Barclays lowered their target price on shares of Sotera Health from $16.00 to $12.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Sotera Health currently has an average rating of "Moderate Buy" and a consensus target price of $15.80.

Sotera Health Price Performance

Sotera Health stock traded down $0.17 during mid-day trading on Thursday, hitting $12.19. The stock had a trading volume of 897,143 shares, compared to its average volume of 1,200,089. The firm has a market capitalization of $3.46 billion, a P/E ratio of 48.76 and a beta of 1.87. The company has a current ratio of 2.88, a quick ratio of 2.61 and a debt-to-equity ratio of 4.91. The firm's 50 day moving average is $11.71 and its 200 day moving average is $12.57. Sotera Health has a one year low of $9.53 and a one year high of $17.08.

Sotera Health (NASDAQ:SHC - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.12 by $0.02. The business had revenue of $254.52 million for the quarter, compared to analysts' expectations of $245.56 million. Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. The business's quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.13 EPS. On average, sell-side analysts forecast that Sotera Health will post 0.61 earnings per share for the current fiscal year.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.